Related projects
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Amphotericin B is the most effective, and frequently the only treatment available for a number of life-threatening diseases, including systemic fungal infections and visceral leishmaniasis. The drawbacks of today’s amphotericin B treatment are toxicity and the need to administer the drug intravenously in hospital settings. The need for intravenous administration is due to poor absorption of the drug following oral administration and greatly increases the costs of the therapy and complications associated with intravenous admnistration. In addition, due to the intravenous administration, the drug is failing to reach many patients, especially in developing countries. In this project, amphotericin B will be administered orally to rats in a number of lipid-based formulations with potential to improve the intestinal absorption of this drug. The concentrations of amphotericin B will be measured in plasma and tissues of animals in order to quantify the extent of absorption of amphotericin B following oral administration in lipid-based formulations.
Dr. Kishor Wasan
Pavel Gershkovich
iCo Therapeutics Inc.
Pharmacy / Pharmacology
Pharmaceuticals
University of British Columbia
Accelerate
Discover more projects across a range of sectors and discipline — from AI to cleantech to social innovation.
Find the perfect opportunity to put your academic skills and knowledge into practice!
Find ProjectsThe strong support from governments across Canada, international partners, universities, colleges, companies, and community organizations has enabled Mitacs to focus on the core idea that talent and partnerships power innovation — and innovation creates a better future.